JSPRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Jasper Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$0.48−0.00 (-0.52%)
Close on Oct 19, 2026
- Market cap
- $13.70M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$1.9726 (−80.51%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $13.70M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 9.70
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$31.77M
- EPS, diluted
- -$1.59
- Book value per share
- $0.05
- Diluted shares
- 29M
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Operating income
-$55.16M
Net income
-$31.77M
EPS, diluted
-$1.59
Reported periodTrailing twelve months